SBS reminds investors about Capricor securities class action over Deramiocel claims

By Atlas Watchline Staff · Legal · August 6, 2026

Schall, Brown & Schwartz LLP says investors may have claims in a securities class action alleging Capricor Therapeutics made misleading statements tied to Deramiocel and a BLA resubmission.

Schall, Brown & Schwartz LLP said Aug. 6 that it is reminding investors about a securities class action against Capricor Therapeutics, Inc. over alleged false and misleading statements tied to Deramiocel and a Biologics License Application resubmission.

The law firm’s press release says the case covers investors who bought Capricor shares between Dec. 17, 2025, and July 26, 2026.

The complaint seeks to represent investors who say they were harmed when the market learned more about the company’s disclosures and the FDA review process, according to the release.

In the press release, Schall, Brown & Schwartz says the complaint alleges violations of Section 10(b), Section 20(a) and SEC Rule 10b-5. The firm says the lawsuit centers on claims that Capricor changed the statistical analysis plan used to review clinical data for Deramiocel, even though, according to the release, the FDA had not agreed to changes from the pre-specified plan before the company resubmitted its BLA.

The release also says Capricor faced a significant risk that the FDA would not approve the BLA for Deramiocel because of insufficient evidence of effectiveness. Those are allegations in the complaint, and the press release does not provide independent confirmation.

According to the notice, the class has not yet been certified, and investors are not represented by an attorney until certification occurs. The release says shareholders who purchased CAPR shares during the class period may contact the firm about possible lead plaintiff appointments, but lead plaintiff status is not required to participate in any recovery.

The press release lists Brian Schall and David Schwartz as contacts at the firm in Los Angeles.

Sources

• PR Newswire press release from Schall, Brown & Schwartz LLP

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.

This is the AMP version of the article. Read the full article on Atlas Watchline.